

Molecular Characterization Of Plasmid-Mediated Extended Spectrum Beta-Lactamase Resistance In Urinary *Escherichia Coli* From Patients In General Hospital, Maitama, Abuja, Nigeria

ABSTRACT

Aims: This study investigates and reports the production of extended spectrum beta-lactamase in *Escherichia coli* isolates from urine of patients sourced from General Hospital, Maitama, Abuja, Nigeria

Study design: Cross sectional study

Place and Duration of Study: Department of Microbiology, Nasarawa State University, Keffi, between August 2020 and February 2022.

Methodology: *Escherichia coli* was isolated from the samples using standard cultural and microbiological methods. Antibiotic susceptibility testing and minimum inhibitory concentrations were evaluated as described by the Clinical and Laboratory Standards Institute (CLSI). The detection of ESBL production in *E. coli* isolates was carried out using double disc synergy test. In addition, molecular detection of ESBL genes was carried out using Polymerase Chain Reaction (PCR) method.

Results: 27.5% of samples isolated (33/120) had *E. coli*. Antibiotic resistance in the isolates in decreasing order were as follows: sulphamethoxazole/trimethoprim (91.7%), amoxicillin/clavulanic acid (72.2%), ceftriaxone (69.7%), cefotaxime (66.7%), ciprofloxacin (42.4%), meropenem (42.4%), ofloxacin (39.4%), imipenem (39.4%), gentamicin (33.3%), and nitrofurantoin (20.3%). The most common antibiotic resistant phenotypes were CTX-AMC-OFX-CRO-SXT-CIP-NET-IMP-MOR (16.7%) and CTX-AMC-OFX-CRO-CN-SXT-CIP-NET-IMP-MOR (16.7%). Multiple antibiotic resistance (MAR) was observed in 96.6% (29/30) of the isolates with the common MAR indices being 0.2 (23.3%), 0.9 (16.7%), and 1.0 (16.7%). Six of the twenty six cefotaxime/ceftriaxone jointly resistant isolates (23.1%) were confirmed ESBL producers. All six of the ESBL positive isolates (100.0%) carried *bla* genes as follows: *bla*_{TEM} (6/6, 100.0%), *bla*_{SHV} (2/6, 33.3%), and *bla*_{CTX-M} (6/6, 100.0%).

Conclusion: The *E. coli* isolates were less resistant to nitrofurantoin, gentamicin, imipenem, ofloxacin and meropenem. In addition, ESBL genes were detected in confirmed *E. coli* isolates.

Keywords: *Escherichia coli*; ESBL; antibiotics resistance; susceptibility; gene.

1. INTRODUCTION

Escherichia coli is known to be a major pathogen which causes a wide spectrum of clinical manifestations, and diseases including UTIs, pneumonia, bacteremia, meningitis and abdominal infections" [1]. "Antimicrobial such as beta-lactam namely; extended spectrum cephalosporins and penicillins; fluoroquinolones and aminoglycosides are among the most common agent prescribed for treatment of infection caused by Gram negative Enterobacteriaceae"[2, 3]. "Cephalosporins are also widely used for treatment of UTIs due to their potency, broad-spectrum of activity and safety profile" [2].

The World Health Organization has recently included ESBL producing *E. coli* and many other Enterobacteria in the WHO global priority pathogens list as "priority 1", critical [2], - and the Center for Disease Control and prevention has also classified these resistant bacteria in the category of "serious threat" based on the clinical and economic impact, incidence of transmissibility and barrier to prevention [3]. In Nigeria, the health sector is not exempted from the challenge of antimicrobial resistance, especially from organisms such as *E. coli* [4].

"The use of antibiotics is considered as a great factor in the emergence, selection and dissemination antibiotic-resistant organisms in medicine" [5]. "The trend of antimicrobial resistance among *E. coli* in hospitals and health care centres is a cause of concern especially due to the possibility and potential for the transfer of these pathogens to the human population" [5]. "Recently, 60.0% ESBL producing *E. coli* were associated with suspected cases of UTIs in Abuja and other parts of Nigeria"[6, 7, 8]. [9] also identified ESBL and ciprofloxacin co-resistance strain A and B as the most common strains associated with suspected cases of UTIs in tertiary hospitals, Nasarawa State, Nigeria. This study however investigates the antimicrobial resistance profiles, and ESBL resistance genes of the ESBL producing isolates from urine of patients with suspected UTIs in Maitama, Abuja, Nigeria.

2. MATERIALS AND METHODS

2.1 Materials

2.1.1 Media

Bacteriological media that were used in this study included: MacConkey Agar (MCA), Mueller-Hinton Agar (MHA), Nutrient agar (NA), Luria-Bertani (LB) broth, Eosine Methylene Blue (EMB) Agar, Nutrient Broth (NB), Simmons Citrate Agar (SCA), Methyl red/Voges-Proskauer (MR/VP) medium and Peptone water (PW).

2.1.2 Equipment

The equipment used in this study include: Autoclave, Oven, Incubator, Refrigerator/Freezer, Thermocycler, Gel electrophoresis machine, Laminar air flow cabinet, Microscope, Spectrophotometer, UV illuminator, Centrifuge, Touch plate Super Mixer, Microwave oven, Electronic weighing balance, Vortex machine, and Gel Doc system.

2.1.3 Chemicals and reagents

"The chemicals and reagents used in this study included: Carbofuschin, Crystal violet, Ethanol, Creatinine, Potassium hydroxide and Kovac's reagents, obtained from BDH chemical Ltd, England; Ethidium bromide, Iodine solution, EDTA and Glycerol". [43]

2.1.4 Bacteria Isolates

Confirmed *E. coli* isolates from the urine of patients were obtained and used for this study.

The antibiotic resistance profiles of the isolates are as shown in Table 4.

2.1.5 Study Location

The study was carried out at the General Hospital, Maitama, Abuja (GHM). GHM is a 350 - bed hospital (Secondary health facility) located in, Maitama, a place in the Federal Capital Territory of Nigeria.

2.2 Methods

2.2.1 Antibiotic Susceptibility Testing

"The antibiotic susceptibility test for *E. coli* isolates was carried out using the Kirby-Bauer disc diffusion method as modified by the Clinical and Laboratory Standards Institute – CLSI" [10]. "Briefly, 5 colonies of *E. coli* isolates were inoculated into 5 ml of Mueller-Hinton broth (MHB) and incubated at 37°C for 24 hours after which the 24-hour Mueller-Hinton broth was standardized to the turbidity equivalent to 0.5 McFarland standards. The 0.5 McFarland standard was prepared as follows: 99.5 ml of 1% ($\frac{v}{v}$) H₂SO₄ + 0.5 ml of 1.172% ($\frac{w}{v}$) BaCl₂·2H₂O. A sterile cotton swab stick was dipped into the standardized *E. coli* suspension and streaked on MHA plates. Antibiotics discs were gently placed on the MHA plates using a pair of sterile forceps and the plates were allowed to incubate at room temperature for 1 hour before re-incubating at 37°C for 17 hours. The discs used include: Amoxicillin/Clavulanic acid (AMC): (10/20 µg), Sulphamethoxazole/ Trimethoprim (SXT :) (25 µg), Ceftriaxone (CRO): (30 µg), Cefotaxime (CTX :) (30 µg), Nitrofurantoin (NET :) (30 µg), Ofloxacin (OFX :) (5 µg), Gentamicin (CN :) (10 µg), Meropenem (MOR :) (30 µg), Ciprofloxacin (CIP :) (5 µg) and Imipenem (IPM :) (30 µg). After incubation, the diameters of the zones of inhibition were measured to the nearest millimeter (mm) using a ruler and the result of the susceptibility test was interpreted using susceptibility breakpoint earlier described by CLSI" [10].

2.2.2 Extended spectrum β-Lactamase production test/ Phenotypic Screening

The phenotypic confirmatory test for ESBL production by isolates resistant to cefotaxime and ceftriaxone was carried out using Double-Disc Synergy Test (DDST) method earlier described by Fetahagic et al. [11]. "Briefly, 10⁵ cfu/ml bacterial suspension was streaked on sterile Mueller-Hinton agar plates and amoxicillin/clavulanic acid (30 µg) disc was placed at the centre of the plate. Cefotaxime (30 µg) and ceftriaxone (30 µg) discs were then placed 15mm (edge-to-edge) from the centre disc. Enhancement of zone of inhibition in the area between the amoxicillin-clavulanic acid disc and any one of the β-lactam discs compared with the zone of inhibition on the far side of the drug disc was interpreted as indicative of the presence of an ESBL in the tested strain". [11]

2.2.3 Molecular detection of extended spectrum β-Lactamase genes

Isolates that were confirmed ESBL producers were screened to detect the presence of some ESBL resistance genes namely: *bla*_{SHV}, *bla*_{TEM} and *bla*_{CTX-M}.

2.2.4 DNA extraction

The bacterial DNA was extracted by a method as earlier described by Abimiku *et al* [12] with minor modification. Ten (10) milliliters of an overnight broth culture of the bacterial isolate in 1 ml Luria-Bertani (LB) were spun at 14000 rpm for 3 minutes. The supernatant was discarded, and the harvested cell pellet was resuspended in 1 ml sterile distilled water and transferred into 1.5 ml centrifuge tube and centrifuged at 14000 rpm for 10 minutes. The supernatant was discarded carefully. The pellet was re-suspended in 100 µl of sterile distilled water by vortexing. The tube was centrifuged again at 14000 g for 10 minutes, and the supernatant was discarded carefully. The cells were re-suspended in 500 µl of normal saline and heated at 95°C for 20 minutes. The heated bacterial suspension was cooled on ice for 10 minutes and spun for 3 minutes at 14000 rpm. The supernatant containing the DNA was transferred to a 1.5-ml microcentrifuge tube and stored at -20°C for other downstream reactions.

Estimation of the concentration, purity and yield of the DNA sample was accessed using absorbance method (measurement of absorbance) with the spectrophotometer (Nanodrop 1000). For DNA concentration, absorbance readings were performed at 260 nm (A_{260}) and the readings were observed to be within the instrument's linear range (0.1 – 1.0). DNA purity was estimated by calculating the A_{260}/A_{280} ratio and this was done by the spectrophotometer's computer software (where A_{260}/A_{280} ratio ranges from 1.7 – 1.9).

2.2.5 DNA amplification of extended spectrum β -Lactamase genes

Simplex Polymerase Chain Reaction (PCR) was performed in order to amplify the ESBL genes being assessed in the isolates. The presence of *bla*_{CTX-M}, *bla*_{SHV} and *bla*_{TEM} genes were tested for using previously published primer sets and conditions. The primer sequences and expected amplicon sizes for each gene are listed in Table 1.

“The reactions were carried out in 20 μ l reaction volume made up of 10 μ l of Mastermix (InqabaBiotectm, South Africa), 0.32 μ l of primers (0.16 μ l each of forward and reverse primers), 3 μ l of DNA and 6.68 μ l of nuclease-free water. The primer concentration stood at 0.2 M. The reaction tubes were placed in the holes of the thermal cyclor and the door of the machine was closed”. [43]

“Conditions for amplification of all the genes during the reactions were set as 3 minutes of initial denaturation at 95°C, followed by 35 amplification cycles of denaturation at 95°C for 30 sec, annealing at 56°C for 40 seconds, initial extension at 72°C for 50 seconds, final extension at 72°C for 3 minutes and a hold at 4°C infinitely”. [43]

2.2.6 Agarose gel electrophoresis

Exactly 7 μ l of the amplified DNA was transferred into the wells of a 1.5% Agarose gel by stabbing the wells using a micropipette and this was done carefully to ensure that each well had only one sample. Each gel had one well which contained a DNA ladder in order to estimate the size of the DNA amplicons. Electrophoresis was run at 125 volts for 20 min, after which the gels were viewed using ultra-violet trans-illuminator.

Table 1. Primers and their sequences

S/N	Target genes	Sequence	Amplicon size (bp)	References
1	<i>bla</i> _{TEM}	5'-TCGGGGAAATGTGCGCG-3' 5'-TGCTTAATCAGTGAGGCACC-3'	972	Saladin <i>et al</i> [13]
2	<i>bla</i> _{SHV}	5'-GGGTTATTCTTATTTGTGCGC-3' 5'-TTAGCGTTGCCAGTGCTC-3'	615	Feizabadi <i>et al</i> [14]
3	<i>bla</i> _{CTX-M}	5'-ACGCTGTTGTTAGGAAGTG-3' 5'-TTGAGGCTGGGTGAAGT-3'	857	Feizabadi <i>et al</i> [14]

3. RESULTS AND DISCUSSION

3.1 Isolation and Identification of *Escherichia coli*

The cultural, morphological and biochemical finger print of *E. coli* isolated from urine of patients in General Hospital, Maitama, Abuja, Nigeria was observed. Pinkish colony on MCA which grew with greenish metallic sheen on EMB agar was Gram negative rod and had biochemical reactions namely: indole-positive, methyl red-positive, Voges- Proskauer-negative, citrate-negative, ONPGpositive, among others indicated *E. coli*.

3.2 Occurrence of *Escherichia coli*

A total of 120 samples were isolated for this study. Thirty-three (33) isolates were confirmed *E. coli*, out of which 6 (13.3%) were from male gender and 27 (36.0%) female as shown on Table 2. The age distribution of the study population was also observed as shown in Table 3.

Table 2. Occurrence of *Escherichia coli* in the urine of patients in relation to Gender

Gender	No. (%) <i>E. coli</i> (n=33)
Male	6(18.1)
Female	27 (81.1)
Total	33

Table 3. Age Distribution of the Study Population

Age (Years)	No. (%) <i>E. coli</i>
≤ 10	1(3.33)
11-20	3 (9.1)
21-30	5 (15.1)
31-40	15 (45.4)
41-50	6 (18.1)
>50	3 (9.1)
Total	33

3.2 Antimicrobial Resistance Profile

The antimicrobial resistance in the *E. coli* isolates from urine of patients attending General Hospital Maitama, Abuja Municipal Area, Nigeria is as shown in Table 4. The resistance in the isolates were as follows sulphamethoxazole/trimethoprim (91.7%), amoxicillin/clavulanic acid (72.2%), ceftriaxone (69.7%), cefotaxime (66.7%), ciprofloxacin (42.4%), meropenem (42.4%), ofloxacin (39.4%), imipenem (39.4%), gentamicin (33.3%), and nitrofurantoin (20.3%).

Table 4. Antimicrobial Resistance pattern of *Escherichia coli* isolates (n=33)

Antibiotic	Resistance (%)
sulphamethoxazole/trimethoprim	30 (90.1%)
amoxicillin/clavulanic acid	24 (72.2%)
Ceftriaxone	23 (69.7%)
cefotaxime	22 (66.7%),
ciprofloxacin	14 (42.4%),
meropenem	14 (42.4%),
Ofloxacin	13 (39.4%)

imipenem	13 (39.4%)
gentamicin	10 (30.3%)
nitrofurantoin	7 (21.2%)

3.3 Antimicrobial Resistance Phenotypes

Resistance to the antibiotics tested was observed in the 30 confirmed *E. coli* isolates. The distribution of the resistant isolates into phenotypes is shown in Table 5. The commonest phenotype was the CTX-AMC-OFX-CRO-SXT-CIP-NET-IMP-MOR, and CTX-AMC-OFX-CRO-CN-SXT-CIP-NET-IMP-MOR combinations all having 5 isolates each (16.7%)

3.4 Multiple Antibiotic Resistance (MAR) Index

Multiple antibiotic resistance (MAR), which is the resistance of microorganisms to at least two (2) antibiotics (as according to Joseph *et al*) [15] was observed in all isolates except one. One isolate (3.3%) had a MAR index of < 0.20. The commonest indices were 0.2 (23.3%), 0.9 (16.7%), 1.0 (16.7%) and 0.3 (13.3%) as shown in Table 6.

3.5 Molecular Detection of Extended Spectrum Beta-lactamase Genes

Six of the thirty ESBL positive *E. coli* isolates (20.0%) carried the *bla* genes as follows: *bla*_{SHV} (2/6; 33.3%), *bla*_{CTX-M} (6/6; 100.0) and *bla*_{TEM} (6/6; 100.0). Some isolates carried two *bla* genes (either of the combinations: *bla*_{CTX-M}, and *bla*_{TEM}; *bla*_{TEM} and *bla*_{SHV}; and *bla*_{TEM}, *bla*_{CTX-M} and *bla*_{SHV}).

Table 5. Antimicrobial Resistance Phenotypes of *Escherichia coli* isolated from urine of patients attending General Hospital in Abuja Municipal Area, Nigeria

Antimicrobial Resistance Phenotypes	General Hospital Maitama (n=30)
SXT	1(3.3)
CTX, AMC	2(6.7)
AMC, CRO	3(10.0)
SXT, CN	2(6.7)
OFX, CIP	1(3.3)
CTX, AMC, SXT	1(3.3)
AMC, SXT, CRO	1(3.3)
CRO, CTX, AMC	1(3.3)
CTX, AMC, CRO, SXT	3(10.0)
CTX, AMC, CN, SXT, CIP, MOR	1(3.3)
CTX, AMC, CRO, CN, SXT, MOR	1(3.3)
CTX, OFX, CRO, CN, SXT, CIP, IMP, MOR	3(10.0)
CTX, AMC, OFX, CRO, SXT, CIP, NET, IMP, MOR	5(16.7)
CTX, AMC, OFX, CRO, CN, SXT, CIP, NET, IMP, MOR	5(16.7)

AMC=Amoxicillin/Clavulanic acid; CTX=Cefotaxime; CRO=Ceftriaxone; CIP=Ciprofloxacin; CN=Gentamicin; IMP=Imipenem; OFX=Ofloxacin; MOR=Meropenem; NET=Nitrofurantoin; SXT=Sulfamethoxazole/Trimethoprim

Table 6. Multiple Antibiotic Resistance (MAR) index of resistant *Escherichia coli* isolated from urine of patients attending General Hospital Maitama, Abuja, Nigeria

No of antibiotics isolate resistant to (a)	No. of antibiotics tested (b)	MAR Index ($\frac{a}{b}$)	No. (%) MAR isolates (n=30)
10	10	1.0	5(16.7)
9	10	0.9	5(16.7)
8	10	0.8	3(10.0)
7	10	0.7	0(0.0)
6	10	0.6	2(6.7)
5	10	0.5	0(0.0)
4	10	0.4	3(10.0)
3	10	0.3	4(13.3)
2	10	0.2	7(23.3)
1	10	0.1	1(3.3)

*MAR isolates are those with resistance to at least two antibiotics [15]




Plate.1: Agarose gel electrophoresis of the amplified *blaCTX-M* genes from the *E. coli* isolates. Lanes 1-3 and 6 represent the *blaCTX-M* bands while Lanes 4 and 5 were negative for *blaCTX-M*. Lane M represents the 1500bp molecular ladder.



Plate 2: Agarose gel electrophoresis of the amplified *blaSHV* genes from the *E. coli* isolates. Lanes 1, 3 and 4 represent the *blaSHV* bands while Lanes 2, 5 and 6 were negative for *blaSHV*. Lane M represents the 1500bp molecular ladder.




Plate 3: Agarose gel electrophoresis of the amplified *blaTEM* genes from the *E. coli* isolates. Lanes 1-3, 5 and 6 represent the *blaTEM* bands while Lane 4 was negative for *blaTEM*. Lane M represents the 1500bp molecular ladder.

3.6 Discussion

There has been a significant increase in the number of infections due to ESBL *E. coli*, and African countries have their fair share. [16]. Many strain of *E. coli* have also been shown to be multi-resistant [17, 18, and 19]. Interestingly, reports have shown that the heavy usage of antibiotics is a risk factor for the acquisition of ESBL-producing organisms and this has resulted in the increase in resistance of many common antibiotics, such as, ampicillin, tetracycline, gentamicin and cephalosporins(third generation) [19].

In this present study, 27.5% of the total samples were found to be carriers of *E. coli*. **Furthermore**, 18.1% of the *E. coli* isolates were discovered to carry ESBL genes. This observation is similar to the findings in other studies that ESBL producing organisms can be found or detected in both community and hospitalized patients with varying prevalence levels;

Odongo *et al.* in Uganda [20] observed a 10% prevalence, and a similar study by Odokiet *et al.* in Uganda [21] showed 41.9%. The varying prevalence in the different studies could be due to population variation and differences in sample sizes. The prevalence was observed to be higher in females (36.0%) than males (13.3%). Many studies have also documented the prevalence of *E. coli* in UTI patients to be higher in females compared to the males [22, 23]. This could be due to the proximity of the anus to the urethra of females the urethral tube of the female is short, hence, the distance travelled by the organism to the bladder is shortened.

The prevalence was high in the age group 31-40 (45.4%), compared to other age groups. The findings are similar to the ones reported by Lin *et al.*, [24] in Taiwan (30%), Asare *et al.*, [25] in Ghana (44%), but differs from studies by, Aiyegoro *et al.* [26], Collingwood *et al.* [27] where juveniles <17 were recorded as prevalent carriers.

In our study, all but one of the isolates (96.7%) were observed to be multiple resistant, that is, resistant to two or more antibiotics (including β lactam antibiotics, trimethoprim-sulfamethoxazole, ciprofloxacin amongst others). Resistance to the antibiotics used was as follows: sulphamethoxazole/trimethoprim (91.7%), amoxicillin/clavulanic acid (72.2%), ceftriaxone (69.7%), cefotaxime (66.7%), ciprofloxacin (42.4%), meropenem (42.4%), ofloxacin (39.4%), imipenem (39.4%), gentamicin (33.3%), and nitrofurantoin (20.3%). The high level of resistance observed to augmentin, sulphamethoxazole/trimethoprim, and ceftriaxone (all >50%) is very likely due to selective pressure as a result of uncontrolled and indiscriminate or inappropriate use of these antibiotics in hospitals and in other places around the country. This could be said to be encouraged by the lack of sufficient knowledge and awareness of the antibiotic policy recently released. The availability of antibiotics hawked and sold over the counter in Nigeria could be said to be a contributing factor.

Very few publications have been made and documented on the molecular characterization of ESBL genes from *E. coli* isolated from urine of patients in hospitals in Abuja. This characterization plays an important role in epidemiological studies as well as management of outbreaks, or even controlling and preventive measures. In this study, 6 of the 30 *E. coli* isolated and confirmed positive for ESBL phenotype (20%) carried ESBL genes. This finding is similar to a study by Wang *et al.* in China (39%), Sadeghi *et al.* in Iran (40%), and Pandit *et al.* in Nepal (40%), [28, 29, 30], but is different from findings by Kuta in Minna (60%) [31], Ugwu *et al.* (60.3%) [32] in Anambra and 93% by Abujnah in Libya [33]. A study by Moghaddam *et al.* [34] in Iran had an ESBL prevalence rate of 33.3%, with all 3 genes bla_{TEM} , bla_{SHV} and bla_{CTX-M} being present. Clearly, the prevalence of ESBL producers varies among clinical isolates from different geographic areas. According to a study by Machado *et al.*, "The presence of ESBL was confirmed in 39% of the *Enterobacteriaceae* isolates resistant to expanded-spectrum cephalosporins in North and center of Portugal over 2 years (2002-4) and 37 out of 133 *E. coli* isolates were ESBL producing". [35] "In another study by Al-Zarouni *et al.* in the UAE, about 38-39% of *E. coli* isolates from Emirate in 2005-6 were identified as having ESBL" [36]. "Much higher prevalence of ESBL has been reported from other places such as Latin America: 30-60%, Turkey: 58%, and India: 56% (2, 20). However, low rates (5-8%) of ESBL-producing *E. coli* have been reported in Korea by Pareson and Bonoma, Japan, Malaysia and Singapore by Lewis *et al.* and Babypadmini" [37, 38, and 39]. Lower than 1% of *E. coli* isolates were reported to be ESBL positive in Netherlands in a study by Stobberinghet *et al.* [40].

According to a study by Quinn *et al.*, "in the United States of America, ESBL-producing *E. coli* isolates, were associated with resistance to co-trimoxazole, nalidixic acid, gentamicin and ciprofloxacin" [41]. "This is quite different from our study where a higher percentage of ESBL positive isolates were resistant to augmentin, sulphamethoxazole/trimethoprim, and ceftriaxone. The high levels of ESBL producers are a major threat to infection and disease management ESBL-producing organisms are known to contain plasmids with genes that encode resistance to quinolones, aminoglycosides, and cotrimoxazole" [42].

4. CONCLUSION

In conclusion, this study has described the emergence of ESBLs among *E. coli* isolates obtained from hospitalized patients in Abuja. Also, similar situation seems to be occurring in other countries; the spread of *E. coli*-producing ESBLs comes as a great challenge to health systems especially in developing countries, and this emphasizes the need for implementation of strict hospital infection control policies, including the review of current therapeutic modalities, control of the use of non-prescribed antibiotics and continuous monitoring of antibiotic sensitivity profiles of *E. coli* isolates.

Escherichia coli, the organism of interest, observed in the UTI patients had a low prevalence. There was a significantly high resistance to trimethoprim/sulfamethoxazole, ciprofloxacin and augmentin. Our findings further illustrated a low prevalence of the ESBL carrying *E. coli* in the hospital environment and the presence of the bla_{CTX} and bla_{TEM} in the *E. coli* isolates. Continuous use of these drugs may be as a result of antimicrobial resistance and treatment failures. Urine culture should be done when UTI is suspected to serve as a guide. There is also a need to continuously monitor antibiotic resistance so as to curb or reduce resistance emergence.

ETHICAL APPROVAL

Appropriate ethical approval was obtained before the start of the study.

REFERENCES

1. Mueller M, Tainter CR. *Escherichia coli* Infection. [Updated 2023 Jul 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK564298/>
2. World Health Organization (2017). WHO publishes list of bacteria for which new antibiotics are urgently needed. <https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed>.
3. Center for Disease Control and Prevention (2019). Antibiotic resistance threat in the United States, U.S. - Department of Health and Human Services, CDC, Atlanta, G.A.
4. Iheanacho, CO, & Eze, UI. Antimicrobial resistance in Nigeria: challenges and charting the way forward. *European Journal of Hospital Pharmacy*. 2022; 29(2), 119-119.
5. Serwecińska, L. Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health. *Water*. 2020; 12(12), 3313.
6. Basse, A., Ngwai, Y.B., Basse, B.E., Nkene, I.H., Abimiku, R.H. and Parom, S.K. Phenotypic and molecular detection of extended spectrum β -lactamase in *Escherichia coli* from patients in Nigerian National Petroleum Corporation Medical Services, Abuja, Nigeria. *Annual Research and Review in Biology*. 2018; 28 (4):1-7.
7. Giwa, FJ, Ige, OT, Haruna, DM, Yaqub, Y, Lamido, TZ. and Usman, SY. Extended-spectrum beta-lactamase production and antimicrobial susceptibility pattern of uropathogens in a tertiary hospital in Northwestern Nigeria. *Annual Tropical Pathology*. 2018; 9:11-16.
8. Medugu, N, Aworh, MK., Iregbu, K, Nwajiobi-Princewill, P, Abdulraheem, K, Hull, DM, Harden, L, Singh, P, Obaro, S, Egwuenu, A. and Thakur, S. Molecular characterization of multi drug resistant *Escherichia coli* isolates at a tertiary hospital in Abuja, Nigeria. *Scientific Report*. 2022; 12:14822.
9. Nkene, IH, Ngwai, YB, Omede, MU, Samuel, J, Envuladu, EY. and Abimiku, RH. Extended spectrum beta-lactamase producing *Escherichia coli* from urine of symptomatic

- and asymptomatic subjects in Keffi, Nigeria. *International Journal of Research Studies in Biosciences*. 2015: 3(12): 1-5.
10. Simner, PJ, Hindler, JA, Bhowmick, T, Das, S, Johnson, JK, Lubers, BV, Erdman, SM. What's New in Antibiograms? Updating CLSI M39 Guidance with Current Trends. *Journal of clinical microbiology*. 2022: 60(10), e02210-21.
11. Fetahagić, M, Ibrahimagić, A, Uzunović, S, Beader, N, Elveđi-Gašparović, V, Luxner, J, &Bedenić, B. Detection and characterisation of extended-spectrum and plasmid-mediated AmpC β -lactamase produced by *Escherichia coli* isolates found at poultry farms in Bosnia and Herzegovina. *Arhivzahigijenuradaitoksikologiju*. 2021: 72(4), 305-313.
12. Abimiku, RH, Ngwai, YB, Nkene, IH, Bassey, BE, Tsaku, PA, Ibrahim, T, &Pennap, G. R. I. Phenotypic detection of extended spectrum beta-lactamase resistance of *Escherichia coli* from patients attending selected healthcare facilities in Nasarawa State, Nigeria. *South Asian Journal of Research in Microbiology*. 2019: 4(3), 1-10.
13. Saladin, M, Cao, VTB, Lambert, T, Donay, JL, Herrmann, JL, Ould-Hocine, Z, &Arlet, G. Diversity of CTX-M β -lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. *FEMS microbiology letters*. 2002: 209(2), 161-168.
14. Feizabadi, MM, Delfani, S, Raji, N, Majnooni, A, Aligholi, M, Shahcheraghi, F, &Yadegarinia, D. Distribution of bla TEM, bla SHV, bla CTX-M genes among clinical isolates of *Klebsiellapneumoniae* at Labbafinejad Hospital, Tehran, Iran. *Microbial drug resistance*. 2010: 16(1), 49-53.
15. Joseph AA, Odimayo MS, Olokoba LB, Olokoba AB, Popoola GO. Multiple antibiotic resistance index of *Escherichia coli* isolates in a tertiary hospital in south-west Nigeria. *Medical Journal of Zambia*. 2017;44(4):225-32.
16. Malande, OO, Nuttall, J, Pillay, V, Bamford, C, & Eley, B. A ten-year review of ESBL and non-ESBL *Escherichia coli* bloodstream infections among children at a tertiary referral hospital in South Africa. *PloS one*. 2019: 14(9), e0222675.
17. Kraupner, N, Hutinel, M, Schumacher, K, Gray, DA., Genheden, M, Fick, J, Larsson, D. J. Evidence for selection of multi-resistant *E. coli* by hospital effluent. *Environment International*. 2021: 150, 106436.
18. Saha, O, Hoque, MN, Islam, OK, Rahaman, MM, Sultana, M, & Hossain, MA. Multidrug-resistant avian pathogenic *Escherichia coli* strains and association of their virulence genes in Bangladesh. *Microorganisms*. 2020: 8(8), 1135.
19. Santos, ACM, Silva, RM, Valiatti TB, Santos, FF, Santos-Neto, JF, Cayô, R, & Gomes, TA. Virulence potential of a multidrug-resistant *Escherichia coli* strain belonging to the emerging clonal group ST101-B1 isolated from bloodstream infection. *Microorganisms*. 2020: 8(6), 827.
20. Odongo, I, Ssemambo, R, &Kungu, JM. Prevalence of *Escherichia Coli* and its antimicrobial susceptibility profiles among patients with UTI at Mulago Hospital, Kampala, Uganda. *Interdisciplinary perspectives on infectious diseases*. 2020.
21. Odoki, M, AlmustaphaAliero, A, Tibyangye, J, NyabayoManiga, J, Wampande, E, Drago Kato, C, &Bazira, J. Prevalence of bacterial urinary tract infections and associated factors among patients attending hospitals in Bushenyi district, Uganda. *International journal of microbiology*, 2019.
22. Fatima, T, Rafiq, S, Iqbal, A, &Husnain, S. Prevalence and Antibiogram of MDR *E. coli* strains isolated from UTI patients—1-year retrospective study at Nishtar Medical Hospital, Multan. *SN Comprehensive Clinical Medicine*. 2020: 2(4), 423-431.
23. Assafi, MS, Ali, FF, Polis, RF, Sabaly, NJ, &Qarani, SM. An Epidemiological and Multidrug Resistance Study for *E. coli* Isolated from Urinary Tract Infection (Three Years of Study). *Baghdad Science Journal*. 2022: 19(1), 0007-0007.
24. Lin, WH, Zhang, YZ, Liu, PY, Chen, PS, Wang, S, Kuo, PY, & Kao, CY. Distinct characteristics of *Escherichia coli* isolated from patients with urinary tract infections in a medical center at a ten-year interval. *Pathogens*. 2021: 10(9), 1156.

25. Asare, KK, Amoah, S, Coomson Jr, CA, Banson, C, Yaro, D, Mbata, J, & Opoku, YK. Antibiotic-resistant pathogenic bacterial isolates from patients attending the outpatient department of university of Cape Coast hospital, Ghana: A retrospective study between 2013–2015. *PLoS Global Public Health*. 2022: 2(5), e0000417.
26. Aiyegoro, OA, Igbinosa, OO, Ogunmwonyi, IN, Odjadjare, EE, Igbinosa, OE, & Okoh, A I. Incidence of urinary tract infections (UTI) among children and adolescents in Ile-Ife, Nigeria. *Afr J Microbiol Res*. 2021: 1(2), 13-19.
27. Collingwood, JD, Yarbrough, AH, Boppana, SB, & Dangle, PP. Increasing prevalence of pediatric community-acquired UTI by extended spectrum β -lactamase-producing *E. coli*: cause for concern. *The Pediatric Infectious Disease Journal*. 2023: 42(2), 106-109.
28. Wang, G, Zhu, Y, Feng, S, Wei, B, Zhang, Y, Wang, J, & Cui, W. Extended-spectrum beta-lactamase-producing Enterobacteriaceae related urinary tract infection in adult cancer patients: a multicenter retrospective study, 2015–2019. *BMC Infectious Diseases*. 2023: 23(1), 1-11.
29. Sadeghi, M, Ebrahim-Saraie, HS, & Mojtahedi, A. Prevalence of ESBL and AmpC genes in *E. coli* isolates from urinary tract infections in the north of Iran. *New Microbes and New Infections*. 2022: 45, 100947.
30. Pandit, R, Awal, B, Shrestha, SS, Joshi, G, Rijal, BP, & Parajuli, NP. Extended-spectrum β -lactamase (ESBL) genotypes among multidrug-resistant uropathogenic *Escherichia coli* clinical isolates from a teaching hospital of Nepal. *Interdisciplinary perspectives on infectious diseases, 2020*.
31. Kuta, FA. *Escherichia coli* Encoding Extended-Spectrum Beta-Lactamases Isolated from Diarrheic Patients in Minna, Nigeria. *International Journal of Biotechnology*. 2021: 10(2), 52-68.
32. Ugwu, MC, Shariff, M, Nnajide, CM, Beri, K, Okezie, UM, Iroha, IR, & Esimone, CO. Phenotypic and molecular characterization of β -lactamases among enterobacterial uropathogens in Southeastern Nigeria. *Canadian Journal of Infectious Diseases and Medical Microbiology, 2020*.
33. Abubaker A. Abujnah, Abdulaziz Zorgani, Mohamed AM. Sabri, Hanan El-Mohammady, Rania A. Khalek & Khalifa S. Ghenghesh (2015) Multidrug resistance and extended-spectrum β -lactamases genes among *Escherichia coli* from patients with urinary tract infections in Northwestern Libya, *Libyan Journal of Medicine*, 10:1, DOI: [10.3402/ljm.v10.26412](https://doi.org/10.3402/ljm.v10.26412)
34. Moghaddam MN, Forghanifard MM, Moshrefi S. Prevalence and molecular characterization of plasmid-mediated extended-spectrum β -lactamase genes (blaTEM, blaCTX and blaSHV) among urinary *Escherichia coli* clinical isolates in Mashhad, Iran. *Iranian journal of basic medical sciences*. 2012 May;15(3):833.
35. Machado E, Coque TM, Canton R, Novais A, Sousa JC, Baquero F, Peixe L. High diversity of extended-spectrum β -lactamases among clinical isolates of Enterobacteriaceae from Portugal. *Journal of antimicrobial chemotherapy*. 2007 Dec 1;60(6):1370-4.
36. Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. *Medical Principles and Practice*. 2007 Apr 22;17(1):32-6.
37. Paterson DL, Bonomo RA. Extended-spectrum β -lactamases: a clinical update. *Clinical microbiology reviews*. 2005 Oct;18(4):657-86.
38. Group I Includes TJ, Colledge TM, Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN. In vitro evaluation of cefepime and other broad-spectrum β -lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. *Diagnostic microbiology and infectious disease*. 1999 Dec 1;35(4):307-15.

39. Babypadmini S, Appalaraju B. Extended spectrum β -lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae*-prevalence and susceptibility pattern in a tertiary care hospital. *Indian Journal of medical microbiology*. 2004 Jul 1;22(3):172-4.
40. Stobberingh EE, Arends J, Hoggkamp-Korstanje JA, Goessens WH, Visser MR, Buiting AG, Debets-Ossenkopp YJ, Van Ketel RJ, Van Ogtrop ML, Sabbe LJ, Voorn GP. Occurrence of extended-spectrum betalactamases (ESBL) in Dutch hospitals. *Infection*. 1999 Dec;27:348-54.
41. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA. Multiple antibiotic-resistant *Klebsiella* and *Escherichia coli* in nursing homes. *Jama*. 1999 Feb 10;281(6):517-23.
42. Manyahi J, Matee MI, Majigo M, Moyo S, Mshana SE, Lyamuya EF. Predominance of multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili National Hospital, Tanzania. *BMC Research Notes*, 2014;7(1), 500.
43. Tama SC, Ngwai YB, Nkene IH, Abimiku RH. Molecular Detection of Extended Spectrum Beta-lactamase Resistance in *Escherichia coli* from Poultry Droppings in Keffi, Nigeria. *Asian Journal of Medicine and Health*. 2019:1-9.